Statin withdrawal: clinical implications and molecular mechanisms (Q36582678)

15 August 2017

1 reference

title

Statin withdrawal: clinical implications and molecular mechanisms (English)

1 reference

15 August 2017

Luigi X Cubeddu

1

1 reference

15 August 2017

Matthew J Seamon

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

26

1 reference

15 August 2017

issue

9

1 reference

15 August 2017

page(s)

1288-1296

1 reference

Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Treating dyslipidemia with statins: the risk-benefit profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Evolution of NCEP guidelines: ATP1-ATPIII risk estimation for coronary heart disease in 2002. National Cholesterol Education Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Statins do more than just lower cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Statin-associated myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Discontinuation rates for use of statins are high

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Withdrawal of statins increases event rates in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Effect of withdrawal of statin on C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Withdrawal of cerivastatin induces monocyte chemoattractant protein 1 and tissue factor expression in cultured vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Withdrawal of statin treatment abrogates stroke protection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Effects of statins on endothelium and signaling mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

Early Withdrawal of Statin Therapy in Patients With Non–ST-Segment Elevation Myocardial Infarction National Registry of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9.1288

21 January 2018

Identifiers

DOI

10.1592/PHCO.26.9.1288

1 reference

15 August 2017

1 reference